Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension

Current Drug Metabolism

Volumn 14, Issue 2, 2013, Pages 265-269

  Gur, Serap ^a,c   Kadowitz, Philip J ^a   Gokce, Ahmet ^a   Sikka, Suresh C ^a   Lokman, Utku ^b   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Bosentan; Erectile dysfunction; PDE5 inhibitor; Pulmonary hypertension; Sildenafil; Tadalafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; AVANAFIL; BOSENTAN; CIMETIDINE; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; CYTOCHROME P450 INHIBITOR; NITRATE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

AREA UNDER THE CURVE; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FAINTNESS; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; PRESCRIPTION; PULMONARY HYPERTENSION; REVIEW;

EID: 84877984877     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920013804870600     Document Type: Review

References (45)

1. Pharmaceuticals, B.H.C. Product monograph for LEVITRA (vardenafil HCL). Available at: http://www.univgraph.com/bayer/inserts/levitra.pdf. 2010 November 30, 2011].
2. Lilly. CIALIS (tadalafil) prescribing information. Available at: http://pi.lilly.com/us/cialis-pi.pdf. [cited 2011 November 30].
3. Sexual dysfunction: Avanafil is a safe and efficacious treatment for ED. Nat. Rev. Urol., 2012, 9(5), 240.
4. Hoeper, M.M. Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs, 2005, 65(10), 1337-54. (Pubitemid 41043890)
5. Giordano, D.; De Stefano, M.E.; Citro, G.; Modica, A.; Giorgi, M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim. Biophys. Acta, 2001, 1539(1-2), 16-27. (Pubitemid 32522866)
6. Michelakis, E.D.; Tymchak, W.; Noga, M.; Webster, Linda.; Wu, Xi-Chen.; Dien, D. ; Wang, S.-H.; Modry, D.; Archer, S.L. Longterm treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation, 2003, 108(17), 2066-9. (Pubitemid 37337580)
7. Humpl, T.; Reyes, J.T.; Holtby, H.; Stephens, D.; Adatia, I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation, 2005, 111(24), 3274-80. (Pubitemid 40875000)
8. Nichols, D.J.; Muirhead, G.J.; Harness, J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol., 2002, 53 Suppl 1, 5S-12S.
9. Walker, D.K.; Ackland, M.J.; James, G.C.; Muirhead, G.J.; Rance, D.J.; Wastall, P.; Wright, P.A. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica, 1999, 29(3), 297-310. (Pubitemid 29140098)
10. Cheitlin, M.D.; Hutter, A.M. Jr.; Brindis, R.G.; Ganz, P.; Kaul, S.; Russell, R.O. Jr.; Zusman, R.M. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation, 1999, 99(1), 168-77. (Pubitemid 29035976)
11. Ghofrani, H.A.; Osterloh, I.H.; Grimminger, F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov., 2006, 5(8), 689-702. (Pubitemid 44151606)
12. Cheitlin, M.D.; Hutter, A.M. Jr.; Brindis, R.G.; Ganz, P.; Kaul, S.; Russell, R.O. Jr.; Zusman, R.M. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J. Am. Coll. Cardiol., 1999, 33(1), 273-82.
13. Warrington, J.S.; Shader, R.I.; von Moltke, L.L.; Greenblatt, D.J. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab. Dispos., 2000, 28(4), 392-7. (Pubitemid 30185676)
14. Ballard, S.A.; Gingell, C.J.; Tang, K.; Turner, L.A.; Price, M.E.; Naylor, A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol., 1998, 159(6), 2164-71. (Pubitemid 29190800)
15. Rosen, R.C. and J.B. Kostis. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am. J. Cardiol., 2003, 92(9A), 9M-18M. (Pubitemid 37386271)
16. Gupta, M.; Kovar, A.; Meibohm, B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J. Clin. Pharmacol., 2005, 45(9), 987-1003. (Pubitemid 41192358)
17. Treiber, A.; Schneiter, R.; Häusler, S.; Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos., 2007, 35(8), 1400-7. (Pubitemid 47121782)
18. Barst, R.J.; Ivy, D.D.; Gaitan, G.; Szatmari, A.; Rudzinski, A.; Garcia, A.E.; Sastry, B.K.; Pulido, T.; Layton, G.R.; Serdarevic-Pehar, M.; Wessel, D.L. A randomized, double-blind, placebocontrolled, dose-ranging study of oral sildenafil citrate in treatmentnaive children with pulmonary arterial hypertension. Circulation, 2012, 125(2), 324-34.
19. Yanagisawa, R.; Kataoka, M.; Taguchi, H.; Kawakami, T.; Tamura, Y.; Fukuda, K.; Yoshino, H.; Satoh, T. Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. Circ. J., 2012, 76(5), 1245-52.
20. Hollatz, T.J.; Musat, A.; Westphal, S.; Decker, C.; D'Alessandro, A.M.; Keevil, J.; Zhanhai, L.; Runo, J.R. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl.,2012, 18(6), 686-95
21. Andersen, C.U., M.J. Mulvany, and U. Simonsen. Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. Eur. J. Pharmacol., 2005, 510(1-2), 87-96. (Pubitemid 40312393)
22. Bischoff, E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int. J. Impot. Res., 2004, 16 Suppl 1, S34-7. (Pubitemid 38993082)
23. Setter, S.M.; Iltz, J.L.; Fincham, J.E.; Campbell, R.K.; Baker, D.E. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann. Pharmacother., 2005, 39(7-8), 1286-95. (Pubitemid 40943182)
24. Jing, Z.C.; Yu, Z.X.; Shen, J.Y.; Wu, B.X.; Xu, K.F.; Zhu, X.Y.; Pan, L.; Zhang, Z.L.; Liu, X.Q.; Zhang, Y.S.; Jiang, X.; Galiè, N. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am. J. Respir. Crit. Care Med., 2011, 183(12), 1723-9.
25. Meuleman, E.J.; Review of tadalafil in the treatment of erectile dysfunction. Expert Opin. Pharmacother., 2003, 4(11), 2049-56. (Pubitemid 37408116)
26. Arif, S.A. and Poon, H. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin. Ther., 2011, 33(8), 993-1004.
27. Galiè, N.; Brundage, B.H.; Ghofrani, H.A.; Oudiz, R.J.; Simonneau, G.; Safdar, Z.; Shapiro, S.; White, R.J.; Chan, M.; Beardsworth, A.; Frumkin, L.; Barst, R.J. Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009, 119(22), 2894-903.
28. Frumkin, L. Tadalafil and pulmonary arterial hypertension. Clin. Ther., 2012, 34(1), 257.
29. Takatsuki, S.; Calderbank, M.; Ivy, D.D. Initial Experience With Tadalafil in Pediatric Pulmonary Arterial Hypertension. Pediatr. Cardiol., 2012, 33(5), 683-8
30. Wang, R.; Burnett, A.L.; Heller, W.H.; Omori, K.; Kotera, J.; Kikkawa, K.; Yee, S.; Day, W.W.; Didonato, K.; Peterson, C.A. Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability. J. Sex Med., 2012. [Epub ahead of print
31. Zhao, C.; Kim, S.W.; Yang, D.Y.; Kim, J.J.; Park, N.C.; Lee, S.W.; Paick, J.S.; Ahn, T.Y.; Moon, K.H.; Chung, W.S.; Min, K.S.; Suh, J.K.; Hyun, J.S.; Park, K.; Park, J.K. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int., 2012.
32. Kotera, J.; Mochida, H.; Inoue, H.; Noto, T.; Fujishige, K.; Sasaki, T.; Kobayashi, T.; Kojima, K.; Yee, S.; Yamada, Y.; Kikkawa, K.; Omori, K. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J. Urol., 2012, 188(2), 668-74.
33. Hellstrom, W.J.; Freier, M.T.; Serefoglu, E.C.; Lewis, R.W.; Didonato, K.; Peterson, C.A. A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. BJU Int., 2012. [Epub ahead of print].
34. Huddleston, A.J.; Knoderer, C.A.; Morris, J.L.; Ebenroth, E.S. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr. Cardiol., 2009, 30(7), 871-82.
35. Ahsman, M.J.; Witjes, B.C.; Wildschut, E.D.; Sluiter, I.; Vulto, A.G.; Tibboel, D. et al., Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch. Dis. Child Fetal. Neonatal. Ed., 2010, 95(2), F109-14.
36. Galatti, L.; Fioravanti, A.; Salvo, F.; Polimeni, G.; Giustini, S.E. Interaction between tadalafil and itraconazole. Ann. Pharmacother., 2005, 39(1), 200.
37. Loulergue, P.; Gaillard, R.; Mir, O. Interaction involving tadalafil and CYP3A4 inhibition by ritonavir. Scand. J. Infect. Dis., 2011, 43(3), 239-40.
38. Sekar, V.; Lefebvre, E.; De Marez, T.; De Pauw, M.; De Paepe, E.; Vangeneugden, T.; Hoetelmans, R.M. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin. Drug Investig., 2008, 28(8), 479-85. (Pubitemid 351948050)
39. Wilner, K.; Laboy, L.; LeBel, M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br. J. Clin. Pharmacol., 2002, 53 Suppl 1, 31S-36S.
40. Muirhead, G.J.; Wulff, M.B.; Fielding, A et al., Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol., 2000, 50(2), 99-107. (Pubitemid 30612027)
41. Chinello, P.; Cicalini, S.; Pichini, S.; Pacifici, R.; Tempestilli, M.; Petrosillo, N. Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors. Curr. HIV Res., 2012. [Epub ahead of Print
42. Cha, S.H., et al., Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol., 2001, 59(5), 1277-86. (Pubitemid 32385197)
43. Krenzelok, E.P. Sildenafil: clinical toxicology profile. J. Toxicol. Clin. Toxicol., 2000, 38(6), 645-51.
44. Burgess, G.; Hoogkamer, H.; Collings, L.; Dingermanse, J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur. J. Clin. Pharmacol., 2008, 64(1), 43-50.
45. Paul, G. A.; Gibbs, J. S. R.; Boobis, A. R et al., Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol., 2005, 60(1), 107-12. (Pubitemid 40942789)